Free Trial

Walgreens plans to sell another slice of its Cencora stake for $1.1 billion

A Walgreens store in Bradenton, Fla., is shown on Feb. 9, 2024. The struggling drugstore chain Walgreens will get about $1.1 billion for selling another slice of its stake in drug distributor Cencora. (AP Photo/Gene J. Puskar, File)

The struggling drugstore chain Walgreens will get about $1.1 billion for selling another slice of its stake in drug distributor Cencora.

Walgreens said after markets closed Thursday that it will use the proceeds mostly to pay down debt and for general corporate purposes. The deal reduces Walgreens’ stake in Cencora to about 10% from 12%.

Walgreens also said in May that it was selling some Cencora shares for $400 million. That deal shaved its stake in the company down from 13%.

Leaders of Walgreens Boots Alliance Inc. said in late June that they were finalizing a plan to turnaround its U.S. business. That push could result in the closing of hundreds of underperforming stores in the next few years.

The company, like its competitors, has been struggling for years with tight reimbursement for the prescriptions it sells as well as other challenges like rising costs to operate its stores.

The Deerfield, Illinois, company also has been backing away from a plan to add primary care clinics next to some if its stores.

The company started 2024 by cutting the dividend it pays shareholders to get more cash to grow its business. Walgreens reported quarterly results at the end of June that missed analyst earnings expectations. The company cut its forecast for its fiscal year, which ends this month.

Shares of Walgreens have shed more than half their value so far this year while broader indexes have climbed. In premarket trading the shares edged down 9 cents to $11.72.

Cencora shares fell 1.3% to $241.24.

→ Vladimir Lenin was right… (From Porter & Company) (Ad)

Should you invest $1,000 in Cencora right now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines